Biologic & Biosimilar RA Drugs Market Report 2024 - Market Size, Growth Rate, Major Drivers And Key Trends | Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc.

"The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Biologic & Biosimilar RA Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The biologic & biosimilar ra drugs market size has grown strongly in recent years. It will grow from $13.44 billion in 2023 to $14.15 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to market adoption rates, clinical trial outcomes, market share changes, long-term patient outcomes, pricing strategies..

The biologic & biosimilar ra drugs market size is expected to see strong growth in the next few years. It will grow to $18.16 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing biologic drug development, market competition, healthcare policies, patient preferences, clinical research & development.. Major trends in the forecast period include rise in biosimilar market competition, personalized medicine and precision therapy, advancements in drug delivery systems, focus on safety and efficacy, patient-centric healthcare..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Market Segmentation:
The biologic & biosimilar ra drugs market covered in this report is segmented -

1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Major Driver - Growing Geriatric Population And Rising Rheumatoid Arthritis Cases Propel Biologics And Biosimilar Ra Drugs Market
The rising older population and increasing incidence of rheumatoid arthritis are driving the biologics and biosimilar RA drugs market forward. The older population refers to people who are aged 60 years or older. Rheumatoid arthritis is an autoimmune disease in which the immune system of a person attacks its healthy cells, and the joints of the person are affected. Rheumatoid arthritis is most likely to affect people in old age as the immune system gets weaker with old age. Biologics and biosimilar RA drugs are very useful for the treatment of rheumatoid arthritis as compared to conventional drugs. For instance, according to the World Health Organization (WHO), a Switzerland-based specialized health agency of the United Nations, there were about 1 billion people aged 60 and above in the world in 2020 and this population is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, according to the Centers for Disease Control and Prevention, a US-based governmental public health agency, the number of adults suffering from arthritis in the USA is expected to increase to 78.4 million by 2040 while 34.6 million people may suffer from arthritis-related activity limitations. Therefore, the increasing geriatric population along with the increasing RA cases is driving the biologics and biosimilars RA drugs market forward.

Competitive Landscape:
Major companies operating in the biologic & biosimilar ra drugs market report are Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc. .

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Top Trend - Biosimilar Treatment To Provide An Affordable Alternative
New innovations are a key trend in gaining popularity in the biologic & biosimilar RA drugs market. Major companies operating in the biologic & biosimilar RA drugs market are focused on developing biosimilar treatments such as Dual Concentration Biosimilar Options to provide an affordable alternative. For instance, in July 2023, Organon, a US-based healthcare company, and Samsung Bioepis, a South Korea-based biopharmaceutical company, launched HADLIMA, a biosimilar of Humira (adalimumab), in the US. Available in high and low concentrations, HADLIMA aims to enhance access and affordability for patients with autoimmune diseases. The biosimilar is priced at an 85% discount to Humira, contributing to expanded patient access. HADLIMA includes an autoinjector, recognized by the Arthritis Foundation, and a patient support program, """"HADLIMA For You,"""" offering educational resources and co-pay support. It is indicated for various conditions, including rheumatoid arthritis and Crohn's disease. HADLIMA is available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), providing patients with seamless continuity of care.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Biologic & Biosimilar RA Drugs Market Characteristics
3. Biologic & Biosimilar RA Drugs Market Trends And Strategies
4. Biologic & Biosimilar RA Drugs Market - Macro Economic Scenario
5. Biologic & Biosimilar RA Drugs Market Size And Growth
…..
27. Biologic & Biosimilar RA Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.